Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Chou

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Nature Communications|September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancerKevin Chang, Henry M Delavan, Elizabeth Yip, et al.
Cancer Research|June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerArian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2019
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling PathwayVishal Kothari, Jonathan F Goodwin, Shuang G Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Genome-wide CRISPR screens identify PTGES3 as a novel AR modulatorHaolong Li, James E Melnyk, Becky Xu Hua Fu, et al.
Nature Genetics|November 5, 2025
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancerHaolong Li, James E Melnyk, Becky Xu Hua Fu, et al.
Cell|July 24, 2018
Genomic Hallmarks and Structural Variation in Metastatic Prostate CancerDavid A Quigley, Ha X Dang, Shuang G Zhao, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Nature Communications|September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancerKevin Chang, Henry M Delavan, Elizabeth Yip, et al.
Cancer Research|June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerArian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2019
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling PathwayVishal Kothari, Jonathan F Goodwin, Shuang G Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Genome-wide CRISPR screens identify PTGES3 as a novel AR modulatorHaolong Li, James E Melnyk, Becky Xu Hua Fu, et al.
Nature Genetics|November 5, 2025
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancerHaolong Li, James E Melnyk, Becky Xu Hua Fu, et al.
Cell|July 24, 2018
Genomic Hallmarks and Structural Variation in Metastatic Prostate CancerDavid A Quigley, Ha X Dang, Shuang G Zhao, et al.
Pageof 9